Supreme Court Victory Offers Limited Shelter as Bayer Faces Glyphosate Price Squeeze and Settlement Delays

Bayer has retracted its antidumping duty petition for Chinese glyphosate, signaling a shift to market‑driven pricing after a brief trade‑protection push. The move leaves the company exposed to intense price pressure from cheap Chinese generics, a risk the CEO warned could end domestic production. In a parallel legal development, the U.S. Supreme Court ruled that consumers cannot sue Bayer over the absence of a cancer warning on glyphosate labels, overturning a $1.25 million verdict and removing a major liability that had cost the company over $10 billion in litigation. However, a fairness hearing for a $7.25 billion class‑action settlement was postponed to August 19, 2026, adding uncertainty. Bayer has bolstered its balance sheet with a $5 billion bond placement and a €3 billion equity deal with Apollo Global Management, while Fitch affirmed a BBB rating with a negative outlook. Analysts remain divided: Barclays and Berenberg maintain overweight or hold ratings with higher targets, Jefferies stays cautious, and Amundi has increased its stake. The company also announced a hybrid wheat licensing deal with RAGT, targeting early 2030s entry and €1 billion revenue by the mid‑2040s. The near‑term outlook hinges on Crop Science and Pharmaceuticals performance and the Supreme Court relief not being undermined by renewed price erosion. Investors will look to Bayer’s August 4 half‑year report and the rescheduled Missouri hearing on August 19 for further guidance.

(Source：Newscase)